Literature DB >> 10471093

Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists.

D Boulay1, R Depoortere, G Perrault, E Borrelli, D J Sanger.   

Abstract

The dopamine (DA) D2-like family of receptors is comprised of three subtypes, the D2, D3, and D4 receptors. It has been suggested that the potency of DA receptor agonists to produce hypothermia and hypolocomotion in rodents correlates more strongly with the in vitro affinity for, or potency (mitogenesis test) at the D3 than at the D2 subtype. However, it has recently been reported that when tested in DA D3 receptor knock-out mice, several DA D2/D3 receptor agonists (7-OH-DPAT, PD 128907 and quinelorane) induced levels of hypothermia and decreases of locomotor activity similar to those obtained in control (wild-type) mice. These results do not argue in favour of an implication of DA D3 receptors in these in vivo effects. In order to investigate whether the DA D2 receptor is the subtype that mediates hypothermia and hypolocomotion produced by DA D2/D3 receptor agonists, we tested the effects of ip administration of the DA D2/D3 receptor agonists 7-OH-DPAT and PD 128907, on core temperature and locomotor activity in DA D2 receptor knock-out mice (homozygotes: D2(-/-) and heterozygotes: D2(+/-)), and in wild-type (D2(+/+)) mice. 7-OH-DPAT (0.1-3 mg/kg) and PD 128907 (1-10 mg/kg) induced hypothermia and decreased locomotion in D2(+/+) mice, but had no effects in D2(-/-) mice; the magnitude of the hypothermic and locomotor-reducing effects of these two agonists in D2(+/+) mutants was approximately half that of D2(+/+) mice. During the first 10 min in the activity chambers, the level of spontaneous locomotor activity of D2(-/-) individuals was almost 50% below that of D2(+/+) mice; basal locomotor activity of D2(+/-) mice was between that of D2(-/-) and D2(+/+) individuals. Neither type of mutant showed spontaneous catalepsy or deficits in forelimb muscle strength (grip-strength test). These results show that the presence of DA D2 receptors is necessary for the expression of the locomotor- and core temperature-decreasing effects of DA D2/D3 receptor agonists such as 7-OH-DPAT and PD 128907.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471093     DOI: 10.1016/s0028-3908(99)00064-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  33 in total

1.  CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist.

Authors:  Jianyong Chen; Gregory T Collins; Beth Levant; James Woods; Jeffrey R Deschamps; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2011-08-11       Impact factor: 4.345

Review 2.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 3.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

Review 4.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

5.  Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects.

Authors:  Gregory T Collins; Diane M Calinski; Amy Hauck Newman; Peter Grundt; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2008-02-27       Impact factor: 4.030

6.  Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists.

Authors:  Ji-Kyung Choi; Joseph B Mandeville; Y Iris Chen; Peter Grundt; Susanta K Sarkar; Amy H Newman; Bruce G Jenkins
Journal:  Psychopharmacology (Berl)       Date:  2010-07-14       Impact factor: 4.530

7.  Biphasic effect of melanocortin agonists on metabolic rate and body temperature.

Authors:  Beth Lute; William Jou; Dalya M Lateef; Margalit Goldgof; Cuiying Xiao; Ramón A Piñol; Alexxai V Kravitz; Nicole R Miller; Yuning George Huang; Clemence Girardet; Andrew A Butler; Oksana Gavrilova; Marc L Reitman
Journal:  Cell Metab       Date:  2014-06-26       Impact factor: 27.287

8.  Effects of dopamine D(2)-like receptor agonists in mice trained to discriminate cocaine from saline: influence of feeding condition.

Authors:  Gregory T Collins; Jonathan A Jackson; Wouter Koek; Charles P France
Journal:  Eur J Pharmacol       Date:  2014-02-20       Impact factor: 4.432

9.  Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors.

Authors:  Andrea Anzalone; José E Lizardi-Ortiz; Maria Ramos; Claudia De Mei; F Woodward Hopf; Ciro Iaccarino; Briac Halbout; Jacob Jacobsen; Chisato Kinoshita; Marc Welter; Marc G Caron; Antonello Bonci; David Sulzer; Emiliana Borrelli
Journal:  J Neurosci       Date:  2012-06-27       Impact factor: 6.167

10.  Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile.

Authors:  Jianyong Chen; Gregory T Collins; Jian Zhang; Chao-Yie Yang; Beth Levant; James Woods; Shaomeng Wang
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.